BACKGROUND It is widely believed that a reduced cardiac index (CI) is a significant contributor to renal dysfunction in
HF (8) . However, the ESCAPE trial included only patients for whom equipoise regarding the necessity of invasive hemodynamic guidance existed. As a result, it excluded patients where PAC was felt to be indicated clinically for diagnosis or management, potentially missing important associations in "sicker" patients. Additionally, prior studies have not tested for nonlinear or threshold effects or examined subgroups of patients in which reduced cardiac output may be an important driver of renal dysfunction.
As such, the overall goal of the current study was to provide a comprehensive analysis of the association between CI and renal function in both the ESCAPE trial and ESCAPE registry, datasets encompassing a broad spectrum of disease severity inclusive of patients receiving clinically indicated catheterizations.
Using these datasets, we sought to exhaustively evaluate the CI-renal function association looking at nonlinear, threshold, between-patient, withinpatient, and multiple subgroup analyses.
METHODS
Our cohort consisted of patients either randomized to the PAC arm of the ESCAPE trial or enrolled in the PAC registry of the ESCAPE trial. Patients were eligible for enrollment into the PAC registry if they were under the care of an HF specialist at 1 of the 26 sites of the ESCAPE trial and were 16 years of age or older undergoing PAC as part of their HF management strategy during hospitalization (9) (10) (11) hemodynamic data available. CI was assessed at up to 4 time points: baseline (on day of PAC), the day after baseline, the day on which the patient was determined to have "optimal" status by the treating physician, and the last hemodynamic measurement before pulmonary artery catheter removal. Serum creatinine measurements were recorded on admission, hospital days 3, 5, and 7, and at discharge.
Inclusion in the current analysis required at least 1 concomitant pair of CI and serum creatinine measurements. In the ESCAPE trial, the first set of laboratory values were obtained on the day of randomization and patients were not randomized until they were ready to undergo pulmonary artery catheter placement. In the PAC registry, lab values were obtained 0 to 24 h before PAC, with initial hemodynamics recorded at this time.
Renal function was queried using 4 different metrics: estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), serum creatinine, and the BUN to creatinine ratio (BUN/Cr ratio) (13, 14) . The
Chronic Kidney Disease Epidemiology Collaboration equation was used to calculate eGFR for both cohorts (13) . The correlation between CI and eGFR was assessed in the combined cohort using all avail- In the PAC arm of the ESCAPE trial, the longitudinal relationship between CI and the natural log of eGFR was assessed on a subject-specific level using linear mixed effects models. The natural log of the baseline eGFR was included as a fixed effect and random effects were evaluated at the level of the patient. Covariance structures were compared using the Akaike and Bayesian information criteria; a model with unstructured covariance provided the best fit. participants in the ESCAPE trial and the remaining 383 were enrolled in the PAC registry. Baseline characteristics of the population are presented in Table 1 .
Briefly, the cohort consisted predominantly of white males with a median age of 60 years and New York Heart Association functional class III or IV HF. The mean ejection fraction was 23 AE 12% with 8% of patients having a preserved ejection fraction (>40%).
The median eGFR was 52.3 ml/min/1.73 m 2 and 24% of our population had an eGFR of <30 ml/min/1.73 m 2 .
On average, PAC registry patients had higher ejection fraction and CI as well as worse renal function.
Compared with patients in the PAC arm of the ESCAPE trial, registry patients were less likely to have New York Heart Association functional class IV HF symptoms and more likely to be receiving inotropes (Table 1) .
Overall, an inverse correlation was observed between baseline CI and baseline eGFR, such that a higher CI was associated paradoxically with a lower eGFR ( Table 2) ; however, the effect size of this No association between CI and eGFR was observed in the analysis of all CI-eGFR pairs with CI "carried forward" (1,340 data pairs; r ¼ À0.05; p ¼ 0.06).
A nonlinear relationship between CI and renal function was also not detectable ( Figure 1) . Specifically, the use of a 3-knot cubic spline, a 4-knot cubic spline, and a fractional polynomial could not meaningfully provide a better fit to the data than a linear regression ( Figure 1) . Furthermore, no threshold effects were observed; the correlation between CI and eGFR was either nonexistent or inverse in the highest, middle, and lowest tertiles of CI ( Table 2) .
In subgroups of patients with or without preserved ejection fraction, diabetes, or hypertension, a positive relationship with CI was not identifiable across various metrics of renal function ( Table 2) .
Similarly, patient subgroups defined by use of medications such as loop diuretics, beta-blockers, or Table 2) .
Indications for right heart catheterization (RHC), such as suspected cardiogenic shock, inability to wean inotropes, hypotension, and diagnostic uncertainty as to hemodynamic status, did not influence the lack of association between a lower CI and worse renal function ( Table 3) . These results applied to eGFR, BUN, creatinine, and the BUN/Cr ratio. Table 4) .
Associations between markers of decongestion and CI were evaluated in the PAC arm of the ESCAPE trial 
DISCUSSION
The primary finding of this study is the lack of statistically significant associations supporting the hypothesis that low cardiac output is an important driver for renal dysfunction in patients with HF.
Where statistically significant associations were found between metrics of renal function and CI, they There exists a wide belief that reduced cardiac index (CI) contributes to renal dysfunction in patients with heart failure (HF). However, this was not supported when evaluating the association between CI and renal function as measured by estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), creatinine, and BUN-to-creatinine ratio in HF patients undergoing pulmonary artery catheterization. Whiskers represent 1 SD and CI is grouped as top, middle, and bottom third of values in the population. Abbreviations as in Table 1 .
improvement versus worsening in serum creatinine (16) . In a randomized trial of decompensated HF patients, randomization to placebo versus high-dose milrinone (which presumably improved cardiac output in these patients) did not lead to a change in serum creatinine from admission to discharge between groups (17, 18) .
With respect to static eGFR, several generally retrospective single-center studies have reported a null association between baseline eGFR and CI (3, 6, 7, 19) . There has been 1 analysis of the multicenter ESCAPE trial demonstrating no association between CI and baseline eGFR (8) . However, the aim of the prior analysis was to examine whether PAC-guided therapy led to improvement in cardiorenal indices and, as such, it did not query exhaustively the relationship between CI and eGFR on a longitudinal basis using sensitive statistical methodology such as the mixed effects modeling used in the current paper. It also lacked evaluation for subgroup, threshold, nonlinear, or within-patient effects. The current analysis adds significantly to the existing literature, because it: 1) draws from a prospective multicenter trial and registry of clinically indicated RHCs, thus spanning a large spectrum of disease severity; 2) WRF ¼ worsening renal function; other abbreviations as in Table 1 . 
CONCLUSIONS
In a multicenter population of decompensated HF patients undergoing clinically indicated PAC, we were unable to detect a relationship between low cardiac output and renal dysfunction. This lack of association persisted across multiple patient subgroups, different metrics of renal function, and the spectrum of cardiac indices. Overall, these results argue that low cardiac output is not the predominant driver for renal dysfunction in patients presenting with decompensated HF.
